Matthew Herper from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	Trump administration lays off FDA employees - 7 days ago STAT+: How Trump’s ‘fear factor’ is already reshaping American science - 8 days ago Trump administration to fire thousands at health agencies - 8 days ago STAT+: Leaving FDA, Califf is unapologetic — and warns of staff departures - about 2 months ago The biggest medical advances of 2024 - about 2 months ago STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 2 months ago Trump suggests he shares some of RFK Jr.’s concerns about childhood vaccines - 3 months ago STAT+: What could Trump mean for the business of health? Scenarios for an RFK Jr. HHS - 3 months ago STAT+: Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast - 3 months ago STAT+: Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded - 3 months ago STAT+: The end of 23andMe’s drug discovery dream - 3 months ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago STAT+: How will Trump’s election change the FDA? History yields some clues - 4 months ago STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion - 5 months ago STAT+: Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback - 6 months ago STAT+: 23andMe board rejects co-founder Anne Wojcicki’s offer to take company private - 7 months ago STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 8 months ago STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 8 months ago New data show the HPV vaccine prevents cancer in men, too. Why don’t more people get it? - 9 months ago STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more - 9 months ago STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study - 11 months ago STAT+: WHO scientists question Grail’s plan for evaluating its multi-cancer Galleri blood test - 11 months ago STAT+: Roivant CEO: New deals could ‘materialize later this year’ - 11 months ago A study says intermittent fasting is making people drop dead. Oh, come on - 11 months ago STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone - 12 months ago STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest - 12 months ago STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act - 12 months ago STAT+: Pfizer is about to make a big push in cancer. Will investors listen? - 12 months ago STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira - about 1 year ago STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing? - about 1 year ago The highs — and lows — of JPM 2024 you should pay attention to - about 1 year ago STAT+: Nvidia says a biological revolution is happening now. But is it? - about 1 year ago This is the TLDR of JPM Day 1 - about 1 year ago STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves - about 1 year ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - about 1 year ago STAT+: Amy Abernethy to step down as Verily’s chief medical officer in latest departure from company - about 1 year ago STAT+: Pfizer says 2024 profits will fall far below expectations - about 1 year ago STAT+: Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it? - about 1 year ago STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research - about 1 year ago STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - about 1 year ago STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment - over 1 year ago Key questions (and answers) about the historic approval of a CRISPR-based medicine - over 1 year ago Study suggests Covid rebound is far more common with Paxlovid than without - over 1 year ago STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug - over 1 year ago STAT+: After decades in use, heart stents finally beat placebo. It took a bold researcher - over 1 year ago In experiment, electrical stimulation of the spinal cord helps a patient with Parkinson’s to walk - over 1 year ago STAT+: Eli Lilly to pay $200 million for Beam’s share of drugs from gene-editing firm Verve - over 1 year ago STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio - over 1 year ago STAT+: Why Sanofi got shellacked - over 1 year ago STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits - over 1 year ago
2	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	Trump administration lays off FDA employees - 7 days ago Trump administration to fire thousands at health agencies - 8 days ago STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study - 11 months ago
3	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	Trump administration to fire thousands at health agencies - 8 days ago
4	Helen Branswell STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	Trump administration to fire thousands at health agencies - 8 days ago
5	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 2 months ago
6	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast - 3 months ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago The highs — and lows — of JPM 2024 you should pay attention to - about 1 year ago This is the TLDR of JPM Day 1 - about 1 year ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - about 1 year ago
7	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago
8	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion - 5 months ago STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma - about 1 year ago
9	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - 4 months ago
10	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 8 months ago